Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 62 of 186 for:    BUPRENORPHINE AND NALOXONE

An Open-Label, Single-Center Study to Evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc at Steady State Following Once-daily Administration of CASSIPA® in Opioid Dependent Subjects.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04088266
Recruitment Status : Not yet recruiting
First Posted : September 12, 2019
Last Update Posted : September 12, 2019
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceuticals USA

Brief Summary:
The objective of this study is to evaluate the exposure-response relationship between the steady-state plasma concentrations of buprenorphine, norbuprenorphine, naloxone, and total naloxone and the change from baseline in QTc prolongation intervals following administration of CASSIPA® sublingual film (16 mg buprenorphine with 4 mg naloxone) to male and female adult subjects initiating treatment of opioid dependence.

Condition or disease Intervention/treatment Phase
Evaluation of QTc Interval Combination Product: 16 mg buprenorphine with 4 mg naloxone sublingual film Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Open-Label, Single-Center Study to Evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc at Steady State Following Once-daily Administration of CASSIPA® in Opioid Dependent Subjects.
Estimated Study Start Date : January 2020
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
16 mg buprenorphine with 4 mg naloxone sublingual film
CASSIPA® sublingual film 16 mg buprenorphine with 4 mg naloxone
Combination Product: 16 mg buprenorphine with 4 mg naloxone sublingual film
CASSIPA®




Primary Outcome Measures :
  1. Differences in QTcF between baseline and post-dose treatment [ Time Frame: 10 days ]
    Differences between QTcF at each post-treatment time point on Day 1 and Day 10 relative to the baseline on Day -7 (ΔQTcF) will be calculated for every subject.


Secondary Outcome Measures :
  1. Potential for delayed effects [ Time Frame: 60 days ]
    Differences in QTcF between baseline and post-dose treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or non-pregnant, non-lactating female, 18-60 years of age (inclusive), with a Body Mass Index (BMI) of 18.0-35.0 kg/m2 (inclusive).
  2. Seeking initiation of treatment for opioid dependence.
  3. Signed informed consent form, which meets all criteria of current Food and Drug Administration (FDA) regulations.
  4. Female subjects who are of non-childbearing potential must meet one of the following criteria:

    • surgically sterile (e.g., bilateral oophorectomy, tubal ligation, hysterectomy or permanent sterilization procedures), with the procedure performed at least 3 months before the start of Induction
    • naturally postmenopausal (no menses) for at least 1 year before Induction and/or has a documented FSH level ≥ 40 mIU/mL at Screening
  5. Female subjects of childbearing potential must not be pregnant or lactating at Screening as confirmed by a negative quantitative serum pregnancy test with a sensitivity of 5 mIU/mL of human chorionic gonadotropin. Females of childbearing potential must have negative urine pregnancy tests with a sensitivity of 25 mIU/mL at the start of Induction (Day -7), the start of Confinement (Day -2), and at all Follow Up outpatient visits. Women of childbearing potential must agree to the use of a reliable method of contraception (e.g., total abstinence, intrauterine device, a double-barrier method, oral, transdermal, injected or implanted non- or hormonal contraceptive), throughout the study. A sterile sexual partner is not considered an adequate form of birthcontrol. Subjects on hormonal contraceptives must have been on the same hormonal contraceptive for at least one month before Screening and continue throughout the duration of the study.
  6. Has a diagnosis of moderate to severe opioid use disorder per the DSM-5 criteria.
  7. Has a Clinical Opiate Withdrawal Scale (COWS) score of greater than 12 at the start of the Induction period and a COWS score of less than 5 at the start of the Dosing period.
  8. Has successfully completed the Induction period of the study to continue on to the Dosing period.

Exclusion Criteria:

  1. Females who are pregnant, lactating or likely to become pregnant during the study.
  2. Has a diagnosis of moderate to severe substance use disorder, by DSM-5 criteria, for any substances other than opioids or tobacco.
  3. Requires opioid treatment for any ongoing medical condition.
  4. Has sustained a traumatic brain injury (TBI) within 30 days prior to Screening, which, in the opinion of the Investigator, would compromise the safety of the subject or the integrity of the study.
  5. Significant history or current medical condition associated with increased intracranial or cerebrospinal fluid pressure such as intracranial neoplasm, hydrocephalus, idiopathic intracranial hypertension, or a related condition which, in the opinion of the Investigator, would compromise the safety of the subject or the integrity of the study.
  6. Significant history or current medical condition associated with increased intracholedochal pressure such as choledocholithiasis or a related condition which, in the opinion of the Investigator, would compromise the safety of the subject or the integrity of the study.
  7. Significant history or current medical condition compromising respiratory function such as COPD, moderate to severe persistent asthma, cor pulmonale, or a related condition which, in the opinion of the Investigator, would compromise the safety of the subject or the integrity of the study.
  8. Use of antiretroviral drugs within 28 days before Induction.
  9. 9. Use of anticholinergic drugs within 7 days before Induction.
  10. Use of diuretics within 7 days before Induction.
  11. Suicidal ideation within 30 days prior to Screening as assessed by answering "yes" to questions 4 or 5 on the suicidal ideation portion of the C-SSRS. A suicide attempt, interrupted attempt, aborted attempt, or preparatory acts/behavior within 6 months before Screening will also result in exclusion.
  12. History of allergy or hypersensitivity to buprenorphine, naloxone, any component of the drug delivery system, other opioids, or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the integrity of the study.
  13. Significant history or current medical condition or organ dysfunction that in the opinion of the Investigator would compromise the safety of the subject or the integrity of the study, including but not limited to cardiovascular, neurologic, pulmonary, gastrointestinal, hepatic, renal, endocrine, psychiatric and infectious disease.
  14. Diagnosed or treated for cancer within the last 5 years.
  15. History or evidence at Screening of clinically significant 12-lead ECG abnormalities or cardiac arrhythmias (including, but not limited to, significant 1st degree atrioventricular (AV) block, 2nd or 3rd degree AV block, complete left bundle branch block (LBBB), QRS duration > 120 ms, prior evidence of MI) that, in the opinion of the Investigator, would compromise the safety of the subject or the integrity of the study; or a QTc > 450 ms for males and > 470 ms for females using Fredericia formula. ECGs may be repeated as appropriate to confirm values and rule out extraneous results, at the discretion of the Investigator.
  16. History of clinically unstable cardiac disease, including uncontrolled hypertension, unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, myocardial infarction, active myocardial ischemia, or left ventricular hypertrophy.
  17. History of congenital or acquired Long QT syndrome (LQTS), Torsade de Pointes (TdP), or an immediate family member with this condition.
  18. Use of Class IA antiarrhythmic medications (e.g., quinidine, procainamide, disopyramide), Class IC antiarrhythmic medications (e.g., flecainide, propafenone), Class III antiarrhythmic medications (e.g., sotalol, amiodarone, dofetilide, ibutilide, dronedarone) or other medications that prolong the QT interval within 28 days before Induction.
  19. Significant history of chronic hypokalemia, hypomagnesaemia, hypocalcaemia or any electrolyte abnormality that can prolong the QTc interval.
  20. Any clinically significant finding on physical exam, clinical labs or ECG that, in the opinion of the Investigator, would compromise the safety of the subject or the integrity of the study.
  21. History of hypotensive episodes or evidence at screening of orthostatic hypotension. This is defined as either a drop in systolic blood pressure of at least 20 mm Hg or a drop in diastolic blood pressure of at least 10 mm Hg, following a resting supine period of 5 min and a subsequent 2-5 min period of quiet standing.
  22. History of syncopal episodes.
  23. Use of pharmacologic agents known to induce or inhibit Cytochrome P450 3A4 within 30 days before Induction to an extent that, in the opinion of the Investigator, would compromise the safety of the subject or the integrity of the study.
  24. Use of monoamine oxidase inhibitors (MAOI) within 14 days before Induction.
  25. Use of serotonergic drugs within 30 days before Induction. These include, but aren't limited to, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), 5-HT3 receptor antagonists, and other medications that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazadone, tramadol). Triptans (e.g., sumatriptan, zolmitriptan, etc) are permitted at the discretion of the Investigator.
  26. Use of buprenorphine products within 14 days before Induction.
  27. Use of the following CNS depressants within 14 days before Induction: methadone, alcohol, benzodiazepines, barbiturates, tranquilizers, and non-benzodiazepine sedatives (e.g., eszopiclone, zaleplon, zolpidem, doxepin, ramelteon, suvorexant). Muscle relaxants will be permitted at the discretion of the Investigator.
  28. Donation or significant loss of whole blood (480 mL or more) within 30 days or plasma within 14 days before inpatient admission.
  29. Positive test results for HIV, active Hepatitis B (+ HBsAg and +anti-HBc IgM) or active Hepatitis C (asymptomatic Hepatitis C is not excluded).
  30. An ALT or AST level that is greater than three times the upper limit of normal value.
  31. Safety laboratory values, including liver function, that in the opinion of the Investigator would compromise subject safety or pose excessive risk of hepatic events.
  32. Any surgery within 6 months before Screening that, in the opinion of the Investigator, would compromise the safety of the subject or the integrity of the study.
  33. Receipt of any drug as part of a research study within 30 days before Screening.
  34. Positive testing for methadone at Screening.
  35. Positive testing for alcohol, buprenorphine, methadone, hydrocodone, cocaine, amphetamines (including methamphetamine and MDMA), benzodiazepines, or barbiturates prior to beginning Induction on Day -7.
  36. Positive testing for alcohol, methadone, hydrocodone,cocaine, amphetamines (including methamphetamine and MDMA), benzodiazepines, or barbiturates prior to beginning Confinement on Day -2. The only exception will be for benzodiazepines given under the direction of the Investigator in order to treat symptoms of withdrawal.
  37. Employees of the Investigator or research center or their immediate family members.
  38. Inability to understand the requirements of the study and the relative information and are unable or not willing to comply with the study protocol.

Layout table for additonal information
Responsible Party: Teva Pharmaceuticals USA
ClinicalTrials.gov Identifier: NCT04088266     History of Changes
Other Study ID Numbers: 71936002
First Posted: September 12, 2019    Key Record Dates
Last Update Posted: September 12, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Buprenorphine
Naloxone
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists